KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment...

Area of Science:

• Hematology
• Oncology
• Infectious Diseases

Background:

• Multicentric Castleman Disease (MCD) is a heterogeneous lymphoproliferative disorder with complex etiology and pathogenesis.
• MCD is associated with HIV infection, Kaposi sarcoma (KS), B-cell lymphomas (e.g., primary effusion lymphoma - PEL), and Hodgkin lymphoma.
• MCD is characterized by interleukin-6 (IL-6) overproduction, termed human interleukin-6 (hIL-6) syndrome, with viral IL-6 (vIL-6) from KSHV also playing a role.

Purpose of the Study:

• To elucidate the intricate relationships between Multicentric Castleman Disease (MCD), HIV, and KSHV.
• To explore the role of KSHV inflammatory syndrome (KICS) in the context of KSHV-associated MCD.
• To review current and potential therapeutic strategies for KSHV-associated MCD and related disorders.

Main Methods:

• Literature review and synthesis of existing research on MCD, HIV, and KSHV.
• Analysis of the role of IL-6 and its viral homolog in disease pathogenesis.
• Examination of the proposed KSHV inflammatory syndrome (KICS) and its relation to MCD.

Main Results:

• MCD pathogenesis involves complex interactions, including IL-6 overproduction, potentially exacerbated by KSHV-encoded vIL-6.
• KSHV inflammatory syndrome (KICS) is a newly proposed entity related to KSHV reactivation, possibly preceding or overlapping with severe MCD.
• Treatment options are diverse, including monoclonal antibodies, chemotherapy, immune modulators, and antiviral therapies.

Conclusions:

• A deeper understanding of HIV-KSHV coinfection intricacies is crucial for improving management and therapy.
• KICS may represent a significant factor in the inflammatory presentation of severe KSHV-related conditions.
• Integrated therapeutic approaches targeting both the lymphoproliferative and viral components are essential for effective patient care.